Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firms ACT Genomics, Sanomics Merge

NEW YORK – Cancer diagnostic firm ACT Genomics announced on Monday that it has merged with lung cancer diagnostic company Sanomics.

Financial and other terms of the deal were not disclosed.

Both companies are part of the Hong Kong government's business incubator Hong Kong Science and Technology Parks, ACT Genomics said in a statement. The combined firm will offer tissue and liquid-based tests using next-generation sequencing, digital PCR, and gene chips, it added.

It will also provide services for cancer types at different stages in clinical applications and help pharmaceutical companies develop companion diagnostics for drug discovery.

The combined company has four laboratories, with two in Hong Kong, one in Thailand, and one in Taipei, Taiwan. The Hong Kong and Taipei laboratories are accredited by the College of American Pathologists.

The group also has a CAP-accredited lab in Kanagawa, Japan, under its joint venture with Canon Medical Systems, and an additional immunohistochemistry and flow cytometry lab in Taipei under its joint venture with Cerba Research.

Tony Mok, chairman of Sanomics, has become chairman of ACT Genomics with the merger. In a statement, Mok said the team "is ready to make meaningful contributions to the enlarged group with our technical expertise, especially in the field of lung cancer, as well as firsthand clinical experience." He added that the combined resources "will enable us to provide more comprehensive solutions and better services to clinicians."